Group IIA Secretory Phospholipase A

Aged Anti-Inflammatory Agents / therapeutic use Cardiovascular Diseases / enzymology Double-Blind Method Dyslipidemias / drug therapy Female Genetic Predisposition to Disease Group II Phospholipases A2 / blood Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use Incidence Inflammation / drug therapy Male Middle Aged Polymorphism, Single Nucleotide Primary Prevention Prospective Studies Risk Assessment Risk Factors Rosuvastatin Calcium / therapeutic use Time Factors Treatment Outcome
cardiovascular disease inflammation primary prevention risk factor secondary prevention

Journal

Arteriosclerosis, thrombosis, and vascular biology
ISSN: 1524-4636
Titre abrégé: Arterioscler Thromb Vasc Biol
Pays: United States
ID NLM: 9505803

Informations de publication

Date de publication:
06 2019
Historique:
pubmed: 10 5 2019
medline: 6 2 2020
entrez: 10 5 2019
Statut: ppublish

Résumé

Objective- Inflammation is a causal risk factor for cardiovascular disease (CVD). sPLA

Identifiants

DOI: 10.1161/ATVBAHA.118.311894 PMID: 31070471 PMC: PMC6534275
pubmed: 31070471
doi: 10.1161/ATVBAHA.118.311894
pmc: PMC6534275
mid: NIHMS1525760
doi:

Substances chimiques

Anti-Inflammatory Agents 0
Hydroxymethylglutaryl-CoA Reductase Inhibitors 0
Rosuvastatin Calcium 83MVU38M7Q
Group II Phospholipases A2 EC 3.1.1.4
PLA2G2A protein, human EC 3.1.1.4

Banques de données

ClinicalTrials.gov
['NCT00239681']

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1182-1190

Subventions

Organisme : Medical Research Council
ID : G9521010
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : T32 HL007575
Pays : United States
Organisme : Medical Research Council
ID : MC_PC_14089
Pays : United Kingdom
Organisme : Medical Research Council
ID : MR/M009203/1
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_EX_MR/M009203/1
Pays : United Kingdom
Organisme : NHLBI NIH HHS
ID : K24 HL136852
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL117861
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL134811
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL091069
Pays : United States
Organisme : British Heart Foundation
ID : FS/12/82/29736
Pays : United Kingdom

Références

Lancet. 2018 Jan 27;391(10118):319-328
pubmed: 29146124
Curr Opin Lipidol. 2009 Oct;20(5):421-7
pubmed: 19593123
N Engl J Med. 2014 May 1;370(18):1702-11
pubmed: 24678955
Eur Heart J. 2009 Nov;30(22):2742-8
pubmed: 19666896
J Biol Chem. 2014 Apr 4;289(14):10011-23
pubmed: 24523407
Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):839-46
pubmed: 15692105
J Lipid Res. 2005 Feb;46(2):201-10
pubmed: 15576846
Circulation. 2013 Sep 10;128(11):1189-97
pubmed: 24002795
Circ Cardiovasc Genet. 2012 Apr 1;5(2):257-64
pubmed: 22331829
Circulation. 2005 Jun 28;111(25):3481-8
pubmed: 15983262
Curr Cardiol Rep. 2009 Nov;11(6):445-51
pubmed: 19863869
N Engl J Med. 2008 Nov 20;359(21):2195-207
pubmed: 18997196
ACS Med Chem Lett. 2016 Aug 09;7(10):884-889
pubmed: 27774123
Eur J Clin Invest. 2002 Jun;32(6):383-93
pubmed: 12059982
Arterioscler Thromb Vasc Biol. 2013 Mar;33(3):466-73
pubmed: 23349189
Am J Hum Genet. 2011 Jan 7;88(1):76-82
pubmed: 21167468
Circulation. 1999 Sep 21;100(12):1280-4
pubmed: 10491371
Atherosclerosis. 1995 Dec;118(2):173-81
pubmed: 8770312
Chem Rev. 2011 Oct 12;111(10):6130-85
pubmed: 21910409
Circ Res. 2000 Mar 31;86(6):707-14
pubmed: 10747008
Biochem Pharmacol. 2014 Aug 15;90(4):338-48
pubmed: 24907600
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
JAMA. 2014 Sep 10;312(10):1006-15
pubmed: 25173516
N Engl J Med. 2005 Apr 21;352(16):1685-95
pubmed: 15843671
Arterioscler Thromb Vasc Biol. 2013 Dec;33(12):2707-14
pubmed: 24115030
Am J Cardiol. 2000 Oct 1;86(7):718-22
pubmed: 11018189
J Am Coll Cardiol. 2012 Apr 24;59(17):1521-8
pubmed: 22516441
Eur Heart J. 2003 Oct;24(20):1824-32
pubmed: 14563341
JAMA. 2014 Jan 15;311(3):252-62
pubmed: 24247616
Arterioscler Thromb Vasc Biol. 2002 Jul 1;22(7):1213-8
pubmed: 12117740
Circulation. 2012 Feb 14;125(6):757-66
pubmed: 22230483
Cardiovasc Res. 2009 Jan 1;81(1):54-63
pubmed: 18755682
J Am Coll Cardiol. 2013 Nov 19;62(21):1966-1976
pubmed: 23916927
J Am Coll Cardiol. 2005 Oct 4;46(7):1249-57
pubmed: 16198839
Arterioscler Thromb Vasc Biol. 1999 May;19(5):1284-90
pubmed: 10323781
Circulation. 2010 Nov 23;122(21):2183-200
pubmed: 21098459
Eur Heart J. 2012 Dec;33(23):2899-909
pubmed: 22802388

Auteurs

Akintunde O Akinkuolie (AO)

From the Center for Lipid Metabolomics, Division of Preventive Medicine (A.O.A., P.R.L., R.J.G., P.M.R., D.I.C., S.M.), Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (A.O.A.).

Patrick R Lawler (PR)

From the Center for Lipid Metabolomics, Division of Preventive Medicine (A.O.A., P.R.L., R.J.G., P.M.R., D.I.C., S.M.), Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Peter Munk Cardiac Centre, Toronto General Hospital, ON, Canada (P.R.L.).
Heart and Stroke/Richard Lewar Centre for Excellence in Cardiovascular Research, University of Toronto, ON, Canada (P.R.L.).

Audrey Y Chu (AY)

Merck Research Laboratories, Boston, MA (A.Y.C.).

Michael Caulfield (M)

Department of Endocrinology & CVD, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA (M.C., J.M.).

Jianying Mu (J)

Department of Endocrinology & CVD, Quest Diagnostics Nichols Institute, San Juan Capistrano, CA (M.C., J.M.).

Bo Ding (B)

Medical Evidence & Observational Research, Global Medical Affairs (B.D., F.N.), AstraZeneca R&D, Mölndal, Sweden.

Fredrik Nyberg (F)

Medical Evidence & Observational Research, Global Medical Affairs (B.D., F.N.), AstraZeneca R&D, Mölndal, Sweden.
Occupational and Environmental Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden (F.N.).

Robert J Glynn (RJ)

From the Center for Lipid Metabolomics, Division of Preventive Medicine (A.O.A., P.R.L., R.J.G., P.M.R., D.I.C., S.M.), Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Department of Biostatistics, Harvard School of Public Health, Boston, MA (R.J.G.).

Paul M Ridker (PM)

From the Center for Lipid Metabolomics, Division of Preventive Medicine (A.O.A., P.R.L., R.J.G., P.M.R., D.I.C., S.M.), Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Cardiovascular Medicine (P.M.R., S.M.), Department of Medicine, Brigham and Women's Hospital, Boston, MA.

Eva Hurt-Camejo (E)

Cardiovascular & Metabolic Diseases, Innovative Medicines (E.H.-C.), AstraZeneca R&D, Mölndal, Sweden.
Division of Clinical Chemistry, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden (E.H.-C.).

Daniel I Chasman (DI)

From the Center for Lipid Metabolomics, Division of Preventive Medicine (A.O.A., P.R.L., R.J.G., P.M.R., D.I.C., S.M.), Department of Medicine, Brigham and Women's Hospital, Boston, MA.

Samia Mora (S)

From the Center for Lipid Metabolomics, Division of Preventive Medicine (A.O.A., P.R.L., R.J.G., P.M.R., D.I.C., S.M.), Department of Medicine, Brigham and Women's Hospital, Boston, MA.
Cardiovascular Medicine (P.M.R., S.M.), Department of Medicine, Brigham and Women's Hospital, Boston, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Anti-inflammatoires › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Maladies cardiovasculaires › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Méthode en double aveugle › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Troubles du métabolisme lipidique › Dyslipidémies › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Phénomènes génétiques › Génotype › Prédisposition génétique à une maladie › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Enzymes et coenzymes › Enzymes › Hydrolases › Esterases › Carboxylic ester hydrolases › Phospholipases A › Phospholipases A2 › Secretory Phospholipases A2 › Group II Phospholipases A2 › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents régulateurs du métabolisme des lipides › Hypolipémiants › Anticholestérolémiants › Inhibiteurs de l'hydroxyméthylglutaryl-CoA réductase › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Morbidité › Incidence › Group IIA Secretory Phospholipase A
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Inflammation › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Polymorphisme génétique › Polymorphisme de nucléotide simple › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Environnement et santé publique › Santé publique › Pratiques en santé publique › Prévention primaire › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Appréciation des risques › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Rosuvastatine de calcium › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Phénomènes physiques › Temps › Facteurs temps › Group IIA Secretory Phospholipase A
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Group IIA Secretory Phospholipase A